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Trials in “True” Dyslipidemic Patients Are 
Urged to Reconsider Comprehensive Lipid 
Management as a Means to Reduce Residual 
Cardiovascular Risk
José P. Werba1,*, Lorenzo M. Vigo1, Fabrizio Veglia1, Giancarlo Marenzi1, Elena Tremoli1,2 and 
Damiano Baldassarre1,3
Randomized cardiovascular trials aimed to reduce the excessive residual risk in high- risk patients through a more 
aggressive low- density lipoprotein- cholesterol control or targeting triglycerides or high- density lipoprotein- cholesterol 
levels have shown a null or, at best, limited incremental benefit. In some cases, the treatment produced meaningful 
effects only in study subgroups. As a consequence, some compounds were withdrawn (e.g., nicotinic acid derivatives 
and cholesteryl ester transfer protein inhibitors), whereas others (fibrates) are utilized with reluctance due to the low 
level of evidence- based data. By reviewing these trials analytically, we identified a common feature that might 
explain their meager results: most of them involved patients generically at high cardiovascular risk with normal or 
near normal lipid levels and not patients with “true” dyslipidemia, who would receive the treatment if it were part of 
usual care. These observations may warrant re- examining a central criterion of pragmatism, eligibility, in the outline 
of forthcoming cardiovascular trials with novel lipid- modifying drugs.
Morbidity and mortality in patients at high cardiovascular risk 
remain high, even in those receiving the best current standards of 
care. This “residual risk”1 may be attributed to: (i) nonlipid risk 
factors, including inflammatory factors, (ii) persistently high low- 
density lipoprotein- cholesterol (LDL- C) in patients with very 
high baseline levels or statin intolerance, or (iii) concomitant lipid 
abnormalities, such as high triglycerides (TGs), low high- density 
lipoprotein- cholesterol (HDL- C), or high lipoprotein(a). The ad-
vent of proprotein convertase subtilisin/kexin type 9 (PCSK9)- 
inhibitor therapy represents a medical breakthrough for LDL- C 
lowering and residual risk reduction in patients with “hard- to- 
treat” hypercholesterolemia. On the other hand, negative results 
of cardiovascular outcome trials with triglyceride- lowering com-
pounds (fibrates) or HDL- C– raising agents (nicotinic acid deriv-
atives and cholesteryl ester transfer protein (CETP) inhibitors) 
in patients on statins suggest that these treatments do not reduce 
residual risk. Yet, one possible explanation for these negative re-
sults is that most of the patients included in the trials did not have 
the lipid abnormality that the tested interventions actually cor-
rect (Figure 1 and Figures S1–S3). Using an everyday analogy, 
you cannot straighten something that is already straight, even if 
the tool used may successfully straighten something that is bent. 
Indeed, as the relationship between the level of a risk factor and 
the cardiovascular risk is not linear, targeting patients with rela-
tively normal lipid values to achieve “super- normal” values (e.g., 
super- low LDL- C or TGs or super- high HDL- C) may dilute the 
efficacy of the tested intervention toward an effect smaller than 
expected or even yield an overall null result.
We herein describe key features of published explanatory lipid 
trials, not specifically targeted at patients with “true” dyslipidemia, 
who might have undermined the chance to provide definite data 
about the effect of a comprehensive lipid management on residual 
risk, appealing for pragmatic studies.
LDL TRIALS
Early epidemiological studies and evidence from monogenic disor-
ders affecting LDL metabolism have shown that increased concen-
trations of LDL- C are linked with an increased risk of myocardial 
infarction and cardiovascular death. Mendelian randomization 
studies have documented that this association is causal2 and that 
a lifelong exposure even to a few- mg/dL lower LDL- C determines 
a significantly reduced risk of cardiovascular events.3 Relevantly, 
the relationship between LDL- C levels and cardiovascular risk is 
not linear.4 As a consequence, for a given absolute LDL- C reduc-
tion, patients with high LDL- C levels before treatment should 
rationally get from the intervention a larger risk reduction than 
patients with lower baseline levels. The most common form of 
severe hypercholesterolemia encountered in clinical practice is 
observed in patients with familial hypercholesterolemia (FH), a 
disease caused by pathogenic mutations in genes involved in LDL 
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metabolism.5 Heterozygous FH is a relatively frequent condition 
(1:200 to 1:500 in a general population), which determines, if un-
treated, lifelong LDL- C levels usually between 190 and 500 mg/
dL and an at least 10- fold higher risk of premature coronary events 
than that of unaffected individuals.5–7 Accordingly, in current 
prevention guidelines, patients with heterozygous FH are auto-
matically assigned a high- risk category (without the need for risk 
score tools) and recommended precocious and intensive drug treat-
ment.8,9 What may not be so patent is that this treatment recom-
mendation, although undeniably warranted, is based on the lowest 
level of evidence (level C, expert opinion), inasmuch as, weirdly 
enough, not a single controlled LDL- C trial with cardiovascular 
end points has been carried out so far in patients with heterozy-
gous FH. Consequently, no empirical data on the cardiovascular 
effects of LDL- C lowering in patients that fall within the steeper 
part of the LDL- C- related cardiovascular risk are available.
Instead, early randomized controlled trials (e.g., 4S, CARE)10,11 
demonstrated that lowering LDL- C with statins in high- risk pa-
tients with moderate hypercholesterolemia (i.e. LDL- C 140–
190 mg/dL), largely of polygenic plus dietary basis, reduces events 
and mortality. In the studies where an analysis of subgroups ac-
cording to baseline LDL- C was performed, such as in the CARE 
study, baseline LDL- C had a clear influence on the impact on clin-
ical outcomes. Later studies showed that a more intensive LDL- C 
lowering through statins further reduces cardiovascular morbidity, 
but not mortality, compared with less intensive schemes.12 The ad-
dition of ezetimibe to a background of statin therapy was also ef-
fective in reducing the residual risk.13 Thereafter, the concept “the 
lower, the better” pervaded the scientific and clinical communities.
Anti–PCSK- 9 monoclonal antibodies show an exceptionally 
potent LDL- C lowering action and good tolerability. Evolocumab 
and alirocumab, the two compounds that reached the market, 
were tested in full programs of phase III studies (PROFICIO and 
ODYSSEY, respectively) focusing on changes in the lipid profile 
and tolerability in candidates suitable for this type of medicine (i.e., 
high- risk statin- intolerant patients with primary hypercholesterol-
emia and patients with heterozygous FH inadequately controlled 
by standard therapy) (Table 1). However, the two main cardiovas-
cular outcome trials using anti–PCSK- 9 antibodies (FOURIER 
and ODYSSEY OUTCOMES, respectively)14,15 did not target 
these “challenging” patients but rather broad categories of high- 
risk patients with LDL- C levels perhaps not “optimal” but accept-
ably controlled through statins (baseline LDL- C 92 mg/dL in 
FOURIER and 87 mg/dL in ODYSSEY OUTCOMES). These 
values are substantially lower than those of most studies with surro-
gate outcomes that provided backing to regulatory filing (Table 1). 
This might account, at least in part, for the discrepancy between 
the impressive results of exploratory analyses of extension studies 
with evolocumab (OSLER 1- 2)16 and alirocumab (ODYSSEY 
LONG TERM)17 in patients with “true” hypercholesterolemia 
and those of the FOURIER and ODYSSEY OUTCOMES stud-
ies, respectively.
The results of a non- prespecified post hoc subgroup analysis of 
ODYSSEY OUTCOMES give further support to the relevance 
of baseline LDL- C in residual risk reduction with PCSK- 9 in-
hibitors: the number of patients needed to treat to prevent one 
primary event in 2.8 years (the median follow- up) is 29 for those 
with LDL- C ≥ 100 mg/dL (median LDL- C 118 mg/dL) and 125 
(4.3- fold larger) for those with LDL- C < 100 mg/dL. Regrettably, 
these data arise from subgroup analyses and therefore they do not 
provide definite conclusions.
In line with the former data is the comparison of the results of 
cardiovascular trials with bococizumab,18 another monoclonal 
antibody against PCSK- 9: a significant reduction of the primary 
cardiovascular event (hazard ratio: 0.79; 95% confidence interval 
(CI): 0.65−0.97; P = 0.02) was observed in SPIRE- 2 (mean base-
line LDL- C = 134 mg/dL, 7% with heterozygous FH) but not in 
SPIRE- 1 (mean baseline LDL- C = 94 mg/dL, 1.7% with hetero-
zygous FH).
To comprehensively address the impact of baseline LDL- C levels 
on cardiovascular risk reduction, we performed a meta- regression 
analysis of LDL- C cardiovascular trials, stratifying the clinical re-
sponse according to baseline LDL- C levels above or below 100 mg/
dL. The meta- regression scatter plot was constructed using the 
same data on statin trials published by Silverman et al.19 in 2016 
(eFigure S3 in the Supplemental Material of the quoted paper) 
Figure 1 Allegorical sketch representing the distribution of lipid 
trials with cardiovascular outcomes performed so far, according to 
the presence of “true” dyslipidemia at baseline. HDL- C, high- density 
lipoprotein- cholesterol; LDL- C, low- density lipoprotein- cholesterol; TG, 
triglycerides.
Where did most 
cardiovascular lipid 
trials performed so 
far fall into?
Patients with near 
normal or normal
LDL-C, TG or HDL-CPatients with
true
dyslipidemia
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with the addition of seven more recent studies with ezetimibe and 
PCSK- 9 inhibitors.13–18 Data of individual trials included in the 
analysis are shown in Table S1. Figure 2 clearly shows that the rel-
ative risk reduction per 1 mmol/L (1 mmol/L = 38.6 mg/dL) of 
LDL- C reduction is −23% (95% CI: −32% to −13%; P = 0.0002) 
for trials with mean baseline LDL- C levels ≥ 100 mg/dL and −8% 
(95% CI: −22% to +9%; P = 0.22) for those with mean baseline 
LDL- C levels <100 mg/dL. The interaction was statistically sig-
nificant (P = 0.015). These observations are in line with a recent 
meta- analysis20 showing that more intensive—as compared with a 
less intensive—LDL- C lowering produces a greater reduction in 
the risk of total and cardiovascular mortality in patients with base-
line levels of LDL- C above but not below 100 mg/dL. Therefore, 
although a certain benefit may still be obtained from LDL- C low-
ering in high- risk patients without “true” dyslipidemia to LDL- C 
levels typical of healthy neonates (about 30–50 mg/dL), the re-
turn is dramatically lower than in patients with true dyslipidemia.
Looking behind, we can say that the large amount of data pro-
duced in the last 2 decades of prevailing explanatory LDL- C car-
diovascular trials substantiate the pioneering view of Grundy,21 
based at that time just on subgroup analyses of 4S, CARE, and 
WOSCOPS, about the “….need to use clinical judgment as to 
whether to intensify therapy in patients whose LDL cholesterol levels 
are already nearing (these) goals,” which at that time were ≤ 130 mg/
dL in high- risk primary prevention and ≤ 100 mg/dL in secondary 
prevention.
TG TRIALS
The role of blood TG in cardiovascular disease has been under 
scrutiny for decades. A main claim against the atherogenicity of 
high TG is that patients with extremely high TG levels (5,000–
10,000 mg/dL or higher)—due to the so- called familial hyper-
chylomicronemia—do not have a substantially increased risk of 
cardiovascular events.22 Paradoxically, several epidemiological 
studies (reviewed in refs. 22,23) showed that mildly- to- moderately 
increased TG levels (200–800 mg/dL) are associated with coro-
nary heart disease and, in some of these studies, also with isch-
emic stroke and total mortality. This association, however, was 
attenuated or even abrogated after adjustment for standard risk 
factors, casting doubts on whether mildly- to- moderately high TG 
levels are directly deleterious to arteries (i.e., a true risk factor) or 
merely an innocuous bystander or marker of other underlying 
Table 1 Summary of clinical studies with evolocumab and alirocumab showing that the only two RCTs with cardiovascular 
outcomes (FOURIER and ODYSSEY OUTCOMES) were carried out in patients with fairly well- controlled LDL- C at baseline
Program Trial name Na PubMed ID Baseline LDL- C (mg/dL)a Aim of the study
ODYSSEY 
(Alirocumab)
Odyssey FH I 322 26330422 144.7 ± 52.0
Lipid changes and 
safety
Odyssey FH II 166 26330422 134.6 ± 41.2
Odyssey High FH 72 27618825 196.3 ± 57.9
Odyssey Combo I 209 26027630 94.8 ± 29.3
Odyssey Combo II 479 25687353 108 ± 35
Odyssey Mono 52 25037695 141 ± 27
Odyssey Alternative 126 26687696 191.1 ± 72.7
Odyssey Options I 57–47 26030325 103.9 ± 34.9–116.4 ± 37.4
Odyssey Options II 48–53 26638010 94.7 ± 33.6–115.2 ± 48.4b
Odyssey Choice I 312c–37d 27639753 115.4 ± 30.6c–154.7 ± 39.2d
Odyssey Choice II 116–59 27625344 154.1 ± 42.4–167.5 ± 69.0b
Odyssey Long Term 1,553 25773378 122.7 ± 42.6 Lipid changes, safety, CV 
outcomesOdyssey Outcomes 9,462 30403574 87 (73–104)
PROFICIO 
(Evolocumab)
Rutherford- 2 110–110 25282519 155 ± 43–163 ± 50b   
Lipid changes and safety
Taussig 106 28215937 325.9 ± 134.4
Tesla 33 25282520 356 ± 135
Yukawa 205 24662398 143 ± 19
Descartes 145–126 24678979 94.6 ± 12.9–116.8 ± 35.3b
Laplace- 2 1,117 24825642 109.7 ± 42.3
Mendel- 2 153–153 24691094 142 ± 22–144 ± 23b
Gauss- 2 103–102 24694531 192 ± 57–192 ± 61b
Gauss- 3 145 27039291 218.8 ± 73.1
Osler 1- 2 2,976 25773607 120 (97–148) Lipid changes, safety, CV 
outcomesFourier 13,784 28304224 92 (80–109) 
CV, cardiovascular; FH, familial hypercholesterolemia; LDL- C, low- density lipoprotein- cholesterol; RCTs, randomized controlled trials.
aNumber and values in the active group/s. bDifferent groups or assigned doses of proprotein convertase subtilisin/kexin type 9 monoclonal antibody; In Osler 1- 2, 
Fourier, and Odyssey Outcomes LDL- C is expressed as mean (interquartile range); cOn  statins; dOff statins. 
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pathogenic conditions or factors (e.g., diabetes, insulin resistance, 
low HDL- C, high cholesterol in remnant lipoproteins, etc.). This 
uncertainty has been fueled by the inconsistency of the results of 
explanatory TG trials with fibrates. Concisely, compared with pla-
cebo, fibrates reduced major cardiovascular events in primary pre-
vention (Helsinki Heart Study (HHS))24 and in a large secondary 
prevention trial with gemfibrozil (VA- HIT trial)25 but not in 
another one with bezafibrate (Bezafibrate Infarction Prevention 
(BIP) study).26 In these studies, mean baseline TG values were 
176, 160, and 145 mg/dL, respectively, and most patients did not 
have “true” hypertriglyceridemia. Yet, post hoc subgroup analyses 
of HHS and BIP26,27 showed a much more remarkable risk reduc-
tion in patients with high baseline TGs (Table 2). Unfortunately, 
in the design of later trials with fibrates, this piece of informa-
tion was overlooked. In FIELD28 and ACCORD LIPIDS29 
indeed, a fibrate in addition to statins was not significantly su-
perior to placebo in the whole cohorts (which had mean base-
line triglycerides of 150 and 162 mg/dL, respectively), but, again, 
subgroup analyses showed a reduction of major events in patients 
with TGs >204 mg/dL at baseline29,30 (Table 2). A meta- analysis 
shows that fibrates reduce cardiovascular risk by 30% (95% CI: 
19−40%; P < 0.0001) in patients with high TGs and only by 6% 
(95% CI: −2 to 13%; P = 0.13) in those without, with a significant 
heterogeneity between groups (P = 0.0002).31 Thus, fibrates only 
work in the patients under- represented in the trials (Table 2) who 
might customarily have a fibrate prescribed to normalize TGs in 
clinical practice. Yet, because subgroup analyses and meta- analyses 
are the best available experimental evidence, current guidelines as-
sign treatment with fibrates in addition to statins as a low class of 
recommendation.8,9
In the last years, the interest in TG was reignited by the results 
of Mendelian randomization studies, which strongly support a 
causal relationship between genes involved in TG metabolism and 
coronary heart disease.32 Conveniently, it seems that, in this pe-
riod of renewed scientific attention to blood levels of TGs, more 
pragmatism is being adopted in the design of trials aimed to assess 
Figure 2 Relative risk (RR) of major vascular events plotted against the between- group difference in achieved low- density lipoprotein- 
cholesterol (LDL-C) level, stratified by baseline LDL- C level in the experimental group < 100 mg/dL (blue bubbles) or ≥ 100 mg/dL (orange 
bubbles). The tags indicate the acronyms of the randomized LDL- C cardiovascular trials included (25 with statins, 1 with statins plus 
ezetimibe, 6 with inhibitors of proprotein convertase subtilisin/kexin type 9). Meta- regression analysis was performed by weighting each 
study according to the inverse of the variance of the RR. Size of the bubbles is proportional to the weight in the meta- regression. The dashed 
lines represent the meta- regression lines for each strata, and the slopes indicate the risk reduction per 38.6 mg/dL (1 mmol/L) of between- 
group difference in achieved LDL- C level. The difference between the two slopes was assessed by testing the interaction term in the meta- 
regression. CI, confidence interval.
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the efficacy of TG- lowering treatments in reducing residual car-
diovascular risk (see below REDUCE- IT, STRENGTH, and 
PROMINENT).
HDL TRIALS
Epidemiological studies consistently demonstrated that blood lev-
els of HDL- C and risk of coronary heart disease events are linearly 
and inversely correlated with HDL- C values up to about 60 mg/
dL.33–35 However, certain genetic variants associated with high 
concentrations of HDL- C (e.g., in the CETP gene, in the hepatic 
lipase promoter and in the SCARB1 gene) have been associated 
with a high risk of cardiovascular disease,36–38 whereas other ge-
netic variants associated with low concentrations of HDL- C (e.g., 
in the apoA1 gene, in the ABCA1 gene, and in the LCAT gene) do 
not seem to convey an increased cardiovascular risk.39–42 Further 
elements against the cardioprotective role of HDL- C arise from 
the results of Mendelian randomization studies showing no evi-
dent link between genetic variants associated with HDL- C levels 
and cardiovascular risk.32,43,44 Thus, the available data demon-
strating a first criterion of causality (i.e., low HDL- C correlates 
with increased risk) are not fully consistent. Nevertheless, low 
HDL- C is the most common lipid abnormality found in patients 
with premature coronary heart disease,45 and there was strong ex-
pectation that increasing HDL- C through therapy could reduce 
cardiovascular events. The compounds tested in HDL trials were 
nicotinic acid derivatives and CETP inhibitors (briefly “trapibs”). 
Although nicotinic acid had earlier demonstrated efficacy in re-
ducing recurrent myocardial infarction in the CORONARY 
DRUG PROJECT,46 it was not superior to placebo in the statin- 
treated patients of AIM- HIGH47 and HPS2- THRIVE.48 Yet, did 
the patients enrolled in these trials actually have a low HDL- C? 
The available data indicate that most of them did not (Table 3).
CETP inhibitors induce a much greater HDL- C raising effect 
than nicotinic acid, and early studies focusing on lipid changes in 
patients with low HDL- C levels49 had nurtured great expectation. 
However, in the cardiovascular outcome trials ILLUMINATE 
(torcetrapib),50 DAL- OUTCOMES (dalcetrapib),51 and 
ACCELERATE (evacetrapib),52 the trapibs performed not bet-
ter, or even worse, than placebo. The last trapib trial, REVEAL 
(anacetrapib),53 showed a meager 9% relative reduction in the risk 
of events among patients receiving anacetrapib, and the producer 
decided not to submit applications for regulatory approval. It is 
worth noting that baseline HDL- C was in the normal range in 
all these trials (Table 3). Thus, the short life of trapibs was closed 
without a single hard outcome trial in patients at additional risk 
due to low HDL- C. Interestingly, a recent large epidemiological 
study54 demonstrates a U- shaped relationship between HDL- C 
and risk of total and cardiovascular mortality and cardiovascular 
events, with a flat low risk at HDL- C between 40 and 80 mg/dL, 
a sharp rise below 40 mg/dL, and a gradual rise above 80 mg/dL. 
This might explain, at least in part, beyond the theoretical pros 
and cons of CETP inhibition and/or adverse effects of trapibs un-
related to lipid changes, the futility, or even harmfulness of these 
interventions.
Thus, although up- to- date knowledge from observational stud-
ies raises serious doubts about low HDL- C as a causal factor in vas-
cular disease and as a target for therapy, it is also fair to recognize 
that the second criterion of causality (i.e., reversing low HDL- C 
reduces residual cardiovascular risk) has never been truly tested in 
the explanatory HDL trials performed so far.
CRITICAL ASPECTS OF PRAGMATISM NEEDED IN 
CARDIOVASCULAR OUTCOME LIPID TRIALS
Ford and Norrie55 recently stated: “Explanatory trials investigate 
a physiological hypothesis, whereas pragmatic trials inform a clin-
ical or policy decision by providing evidence for adoption of the 
intervention into real- world clinical practice.” The first aspect 
to estimate a trial’s pragmatism is eligibility,56 which is assessed 
through the question: “To what extent are the participants in the 
trial similar to patients who would receive this intervention if it 
was part of usual care?” We believe that for the vast majority of the 
trials mentioned above, the most factual answer is to a minimal 
extent, if any.
Hopefully, pragmatism in trial design will get its place. Potential 
participants in pragmatic trials with emerging LDL- C–lowering 
compounds are patients with LDL- C levels plainly above the goals 
(i.e., with a clinically meaningful gap between the LDL- C goal and 
the LDL- C inclusion criteria) despite using the highest tolerated 
Table 2 Summary of clinical trials with fibrates and cardiovascular outcomes showing that the treatment effect is markedly 
different in the entire cohorts and in subgroups of patients with true hypertriglyceridemia
TRIAL Drug
Primary end 
point: entire 
cohort (P 
value)
Lipid subgroup 
criterion
Primary end 
point: 
subgroup (P 
value)
Prevalence of 
the lipid 
subgroup in 
the whole 
cohort
Type of 
subgroup 
analysis
Heterogeneity in 
treatment effect
HHS Gemfibrozil −34% (0.02) TG > 200 mg/dL 
LDL- C/HDL- C > 5.0
−71% (0.005) 7.3% Post hoc Not assessed
BIP Bezafibrate −7.3% (0.24) TG ≥ 200 mg/dL −39.5% (0.02) 14.8% Post hoc Not assessed
FIELD Fenofibrate −11% (0.16) TG ≥ 204 mg/dL 
HDL- C < 42 mg/dL
−27% (0.005) 20.6% Prespecified P = 0.053 for 
interaction
ACCORD Fenofibrate −8% (0.32) TG ≥ 204 mg/dL 
HDL- C < 34 mg/dL
−31% 17.0% Prespecified P = 0.057 for 
interaction
HDL- C, high- density lipoprotein- cholesterol; LDL- C, low- density lipoprotein- cholesterol; TG, triglyceride.
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doses of consolidated therapy (e.g., statins and/or statins plus ezeti-
mibe). This insufficient response may be due to very high baseline 
lipid levels (such as in some patients with FH), poor individual 
response,57 or intolerance to treatment, which affects about 10% 
of patients on statins58 and rarely patients on ezetimibe. Potential 
participants in pragmatic TG and HDL- C trials are patients with 
TG and HDL- C levels, respectively, frankly within the range as-
sociated with an increased risk of cardiovascular events: TG be-
tween 200 and 800 mg/dL for TG trials and HDL- C ≤ 39 mg/
dL (1 mmol/L) for HDL- C trials. Of note, these HDL- C values 
are not unusual, as they were observed in 16.2% of men and 3.7% 
of women in the general population of a recent large Danish ep-
idemiological study.54 Analogously, we hope that cardiovascular 
trials aimed to evaluate the effect of forthcoming lipoprotein(a)- 
lowering compounds59 will focus on patients at high cardiovascu-
lar risk with hyperlipoprotein(a) and not on patients generically at 
high risk.
WHY DID SO MANY CLINICAL OUTCOME LIPID TRIALS NOT 
FOCUS ON PATIENTS WITH OVERTLY ABNORMAL LIPID 
VALUES?
One claim is the “proof of concept,” which investigates hypoth-
eses, such as “the- lower- the- better” (for LDL- C or TGs) or “the- 
higher- the- better” (for HDL- C). This argument seems timely for 
LDL- C but not for TGs or HDL- C, where there is still a “black 
hole” about the impact of normalization of “true” abnormal levels 
on residual risk. Another possibility is the righteous hope of clin-
ical researchers of reducing residual risk in a broad category of pa-
tients at high risk, independently of their lipid levels. In this case, 
even a small positive result allows claiming a favorable effect on 
the whole category, although many patients (and sometimes most) 
actually get a marginal benefit (see ODYSSEY OUTCOMES 
above). Conversely, a negative overall result may lead to consider 
that the intervention is outright futile, often leading to the with-
drawal of the drug (see HDL trials above), although it might have 
been useful in the right patient. In other cases, positive results in 
subgroup analyses of negative explanatory trials (see FIELD and 
ACCORD LIPIDS above) provide backing to low- class guideline 
recommendations, erratically followed in clinical practice. Last 
but not least, given the high cost of drug development, preclinical 
and clinical testing, and registration, pharmaceutical companies 
may be more interested in endorsing trials whose results (even 
quantitatively small) are potentially applicable to a market large 
enough to cover investments and yield a profit, rather than obtain-
ing larger effects in a more specific but smaller group of treatment 
candidates.
WHO SHOULD PROMOTE AND PERFORM PRAGMATIC 
CARDIOVASCULAR OUTCOME LIPID TRIALS?
The purpose of healthcare stakeholders of evolving toward per-
sonalized evidence- based medicine calls for pragmatism in future 
lipid trials, in order to inform physicians and patients about the 
real cost- effectiveness of a treatment in certain candidates for the 
treatment. The design of some new studies suggests that things are 
hopefully starting to move in this direction.
REDUCE- IT60 was aimed to evaluate the efficacy in reducing 
residual cardiovascular risk of a 4 g daily dose of eicosapentae-
noic acid ethyl ester in patients at elevated cardiovascular risk on 
LDL- C–lowering drugs with fairly well-controlled LDL- C lev-
els (median 74 mg/dL) and baseline fasting TG levels between 
150 and 500 mg/dL (median 216 mg/dL). Even though the 
effect of the therapy on TG levels was mild (18.3%; −39.0 mg 
per deciliter), the treatment produced, after 5 years, a 25% re-
duction of the primary cardiovascular end point. To what extent 
these effects are the result of TG lowering is not clear, as ome-
ga- 3 have many other putative cardioprotective pleiotropic ef-
fects. Yet, the trial pragmatically tested a coherent hypothesis in 
candidates suitable for the intervention in the real- world clinical 
practice, responding to a frequent question of physicians: can we 
reduce residual risk in patients with moderate hypertriglyceri-
demia through omega- 3 fatty acids?
Propitiously, STRENGTH,61 another pragmatic random-
ized placebo- controlled trial with omega- 3 fatty acids in statin- 
treated patients at high risk of developing cardiovascular events, 
with well-controlled LDL- C, hypertriglyceridemia (≥ 180 
to < 500 mg/dL), and low levels of HDL- C (< 42 mg/dL in 
men or < 47 mg/dL in women) is ongoing, and the results are 
awaited by the end of 2019.
Another example of a pragmatic TG- lowering trial in high- 
risk patients is the ongoing PROMINENT trial,62 a randomized, 
double- blind, placebo- controlled cardiovascular outcome trial with 
the novel fibrate compound Pemafibrate. The PROMINENT trial 
plans to recruit high- risk patients with diabetes with and without 
cardiovascular disease, and, for the first time in fibrate outcome tri-
als, all the patients will have TGs >200 mg/dL and low HDL- C de-
spite best evidence- based treatment, including high- intensity statin 
therapy. The results of the PROMINENT trial are awaited by 2022.
Plausibly, the logical sequence of lipid trials with new com-
pounds should recapitulate the history of those performed with 
statins: first, pragmatic studies in patients with definite dyslip-
idemia, then explanatory studies to assess usefulness in broader 
groups. Quoting once again Ford and Norrie55: “…who should pay 
for these [pragmatic] trials… Perhaps the best solution would be 
Table 3 Summary of cardiovascular trials with nicotinic acid 
derivatives or CETP inhibitors showing that most patients 
included in these trials had normal HDL- C levels
Study compound Study name
Baseline HDL- C 
(mg/dL)a
Nicotinic acid
Extended- release niacin AIM- HIGH 34.5 ± 5.6
Extended- release 
niacin + laropiprant
HPS- 2 THRIVE 43.9 ± 11.2
CETP inhibitors
Torcetrapib ILLUMINATE 48.6 ± 12.0
Dalcetrapib DAL- OUTCOMES 42.5 ± 11.7
Evacetrapib ACCELERATE 45.3 ± 11.7
Anacetrapib REVEAL 40 ± 10
CETP, cholesteryl ester transfer protein; HDL- C, high- density 
lipoprotein- cholesterol.
aValues in the active group.
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joint industry–governmental funding.” Definitely highly desirable, 
such a joint venture might be encouraged by regulatory changes 
intended to compensate the industry for taking on the cost and the 
business risk of pragmatic research.
KEY MESSAGES
Performing only explanatory cardiovascular outcome lipid trials 
has important negative consequences: (i) some drugs are with-
drawn prematurely without a specific assessment of efficacy in 
appropriate patients, (ii) physicians prescribe some drugs inconsis-
tently and without certainty due to the low level of evidence- based 
data, and (iii) the cost- effectiveness of the treatment (number 
needed to treat (NNT), number needed to harm (NNH), etc.) 
in certain candidates for the medicine often remains indefinitely 
unknown. Pragmatic trials in individuals with “true” dyslipidemia 
are urged.
SUPPORTING INFORMATION
Supplementary information accompanies this paper on the Clinical 
Pharmacology & Therapeutics website (www.cpt-journal.com).
Figure S1. Mismatch between baseline LDL- C levels at trial entry and 
range of lipid- related high cardiovascular risk (red zone).
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and range of lipid- related high cardiovascular risk (red zone).
Figure S3. Mismatch between baseline HDL- C levels at trial entry and 
range of lipid- related high cardiovascular risk (red zone).
Table S1. Data of cardiovascular LDL- C trials included in Figure 2 (meta- 
regression analysis) of the main manuscript.
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